These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 27740531)

  • 21. Age impacts ability of aspartate-alanine aminotransferase ratio to predict advanced fibrosis in nonalcoholic Fatty liver disease.
    Goh GB; Pagadala MR; Dasarathy J; Unalp-Arida A; Pai RK; Yerian L; Khiyami A; Sourianarayanane A; Sargent R; Hawkins C; Dasarathy S; McCullough AJ
    Dig Dis Sci; 2015 Jun; 60(6):1825-31. PubMed ID: 25708897
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analytical, anthropometric and dietary factors associated with the development of fibrosis in patients with nonalcoholic fatty liver disease.
    Gómez de la Cuesta S; Aller de la Fuente R; Tafur Sánchez C; Izaola O; García Sánchez C; Mora N; González Hernández JM; de Luis Román D
    Rev Esp Enferm Dig; 2018 May; 110(5):292-298. PubMed ID: 29338271
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A novel model using mean platelet volume and neutrophil to lymphocyte ratio as a marker of nonalcoholic steatohepatitis in NAFLD patients: multicentric study.
    Abdel-Razik A; Mousa N; Shabana W; Refaey M; ElMahdy Y; Elhelaly R; Elzehery R; Zalata K; Arafa M; Elbaz S; Hafez M; Awad M
    Eur J Gastroenterol Hepatol; 2016 Jan; 28(1):e1-9. PubMed ID: 26469357
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fatty liver index vs waist circumference for predicting non-alcoholic fatty liver disease.
    Motamed N; Sohrabi M; Ajdarkosh H; Hemmasi G; Maadi M; Sayeedian FS; Pirzad R; Abedi K; Aghapour S; Fallahnezhad M; Zamani F
    World J Gastroenterol; 2016 Mar; 22(10):3023-30. PubMed ID: 26973398
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: assessment of non-invasive indices predicting hepatic steatosis and fibrosis.
    Polyzos SA; Goulis DG; Kountouras J; Mintziori G; Chatzis P; Papadakis E; Katsikis I; Panidis D
    Hormones (Athens); 2014; 13(4):519-31. PubMed ID: 25402369
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The novel cutoff points for the FIB4 index categorized by age increase the diagnostic accuracy in NAFLD: a multi-center study.
    Ishiba H; Sumida Y; Tanaka S; Yoneda M; Hyogo H; Ono M; Fujii H; Eguchi Y; Suzuki Y; Yoneda M; Takahashi H; Nakahara T; Seko Y; Mori K; Kanemasa K; Shimada K; Imai S; Imajo K; Kawaguchi T; Nakajima A; Chayama K; Saibara T; Shima T; Fujimoto K; Okanoue T; Itoh Y;
    J Gastroenterol; 2018 Nov; 53(11):1216-1224. PubMed ID: 29744597
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Incidence and Predictors of Nonalcoholic Fatty Liver Disease by Serum Biomarkers in Patients with Inflammatory Bowel Disease.
    Bessissow T; Le NH; Rollet K; Afif W; Bitton A; Sebastiani G
    Inflamm Bowel Dis; 2016 Aug; 22(8):1937-44. PubMed ID: 27379445
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Liver fibrosis: which are independent predictors?
    Federico A; Dallio M
    Minerva Med; 2019 Jun; 110(3):183-184. PubMed ID: 30989998
    [No Abstract]   [Full Text] [Related]  

  • 29. Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers.
    Vilar-Gomez E; Chalasani N
    J Hepatol; 2018 Feb; 68(2):305-315. PubMed ID: 29154965
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Probiotics and synbiotics may improve liver aminotransferases levels in non-alcoholic fatty liver disease patients.
    Buss C; Valle-Tovo C; Miozzo S; Alves de Mattos A
    Ann Hepatol; 2014; 13(5):482-8. PubMed ID: 25152979
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Circulating periostin in patients with nonalcoholic fatty liver disease.
    Polyzos SA; Kountouras J; Anastasilakis AD; Papatheodorou A; Kokkoris P; Terpos E
    Endocrine; 2017 May; 56(2):438-441. PubMed ID: 27738886
    [No Abstract]   [Full Text] [Related]  

  • 32. Effects of vitamin D supplementation on liver fibrogenic factors in non-alcoholic fatty liver patients with steatohepatitis: study protocol for a randomized clinical trial.
    Ebrahimpour-Koujan S; Sohrabpour AA; Foroughi F; Alvandi E; Esmaillzadeh A
    Trials; 2019 Mar; 20(1):153. PubMed ID: 30832722
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Non-alcoholic fatty liver: position document of the Catalan Society of Gastroenterology].
    Caballería L; Saló J; Berzigotti A; Planas R; Vila C; Huertas C; Torres M; Torán P; Caballería J;
    Gastroenterol Hepatol; 2014; 37(6):372-83. PubMed ID: 24746904
    [No Abstract]   [Full Text] [Related]  

  • 34. Utility and limitations of noninvasive fibrosis markers for predicting prognosis in biopsy-proven Japanese non-alcoholic fatty liver disease patients.
    Ito T; Ishigami M; Ishizu Y; Kuzuya T; Honda T; Hayashi K; Nishimura D; Toyoda H; Kumada T; Goto H; Hirooka Y
    J Gastroenterol Hepatol; 2019 Jan; 34(1):207-214. PubMed ID: 30144360
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Factors predicting non-alcoholic steatohepatitis (NASH) and advanced fibrosis in patients with non-alcoholic fatty liver disease (NAFLD).
    Tasneem AA; Luck NH; Majid Z
    Trop Doct; 2018 Apr; 48(2):107-112. PubMed ID: 29145775
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The AST/ALT ratio as an indicator of cirrhosis in patients with PBC.
    Nyblom H; Björnsson E; Simrén M; Aldenborg F; Almer S; Olsson R
    Liver Int; 2006 Sep; 26(7):840-5. PubMed ID: 16911467
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis.
    McPherson S; Hardy T; Dufour JF; Petta S; Romero-Gomez M; Allison M; Oliveira CP; Francque S; Van Gaal L; Schattenberg JM; Tiniakos D; Burt A; Bugianesi E; Ratziu V; Day CP; Anstee QM
    Am J Gastroenterol; 2017 May; 112(5):740-751. PubMed ID: 27725647
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of transient elastography, serum markers and clinical signs for the diagnosis of compensated cirrhosis.
    Malik R; Lai M; Sadiq A; Farnan R; Mehta S; Nasser I; Challies T; Schuppan D; Afdhal N
    J Gastroenterol Hepatol; 2010 Sep; 25(9):1562-8. PubMed ID: 20796156
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Plasma levels of folate and vitamin B(12) in patients with chronic liver disease].
    Muro N; Bujanda L; Sarasqueta C; Gil I; Hijona E; Cosme A; Arenas J; Elosegui ME; Sarasola M; Calpasoro J; Arenas JI
    Gastroenterol Hepatol; 2010 Apr; 33(4):280-7. PubMed ID: 20206409
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Contemporary assessment of hepatic fibrosis.
    Bonder A; Tapper EB; Afdhal NH
    Clin Liver Dis; 2015 Feb; 19(1):123-34. PubMed ID: 25454300
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.